Autocrine signaling is a key regulatory element during osteoclastogenesis

被引:53
作者
Kopesky, Paul [1 ]
Tiedemann, Kerstin [2 ,3 ]
Alkekhia, Dahlia [1 ]
Zechner, Christoph [1 ]
Millard, Bjorn [1 ]
Schoeberl, Birgit [1 ]
Komarova, Svetlana V. [2 ,3 ]
机构
[1] Merrimack Pharmaceut, Cambridge, MA 02139 USA
[2] Shriners Hosp Children Canada, Montreal, PQ H3G 1A6, Canada
[3] McGill Univ, Fac Dent, Montreal, PQ H3A 0C7, Canada
关键词
Cytokine; High content imaging; Interleukin-8; Osteoclastogenesis; PLSR; BONE-RESORPTION; PROMOTES OSTEOCLASTOGENESIS; OSTEOPROTEGERIN LIGAND; CELL CARCINOMA; GROWTH-FACTOR; DIFFERENTIATION; DESTRUCTION; STIMULATION; OSTEOLYSIS; EXPRESSION;
D O I
10.1242/bio.20148128
中图分类号
Q [生物科学];
学科分类号
090105 [作物生产系统与生态工程];
摘要
Osteoclasts are responsible for bone destruction in degenerative, inflammatory and metastatic bone disorders. Although osteoclastogenesis has been well-characterized in mouse models, many questions remain regarding the regulation of osteoclast formation in human diseases. We examined the regulation of human precursors induced to differentiate and fuse into multinucleated osteoclasts by receptor activator of nuclear factor kappa-B ligand (RANKL). High-content single cell microscopy enabled the time-resolved quantification of both the population of monocytic precursors and the emerging osteoclasts. We observed that prior to induction of osteoclast fusion, RANKL stimulated precursor proliferation, acting in part through an autocrine mediator. Cytokines secreted during osteoclastogenesis were resolved using multiplexed quantification combined with a Partial Least Squares Regression model to identify the relative importance of specific cytokines for the osteoclastogenesis outcome. Interleukin 8 (IL-8) was identified as one of RANKL-induced cytokines and validated for its role in osteoclast formation using inhibitors of the IL-8 cognate receptors CXCR1 and CXCR2 or an IL-8 blocking antibody. These insights demonstrate that autocrine signaling induced by RANKL represents a key regulatory component of human osteoclastogenesis.
引用
收藏
页码:767 / 776
页数:10
相关论文
共 43 条
[1]
Complex Dynamics of Osteoclast Formation and Death in Long-Term Cultures [J].
Akchurin, Timur ;
Aissiou, Tayeb ;
Kemeny, Naomi ;
Prosk, Erin ;
Nigam, Nilima ;
Komarova, Svetlana V. .
PLOS ONE, 2008, 3 (05)
[2]
Notch Pathway Activation Contributes to Inhibition of C2C12 Myoblast Differentiation by Ethanol [J].
Arya, Michelle A. ;
Tai, Albert K. ;
Wooten, Eric C. ;
Parkin, Christopher D. ;
Kudryavtseva, Elena ;
Huggins, Gordon S. .
PLOS ONE, 2013, 8 (08)
[3]
Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-κB ligand pathway [J].
Bendre, MS ;
Margulies, AG ;
Walser, B ;
Akel, NS ;
Bhattacharrya, S ;
Skinner, RA ;
Swain, F ;
Ramani, V ;
Mohammad, KS ;
Wessner, LL ;
Martinez, A ;
Guise, TA ;
Chirgwin, JM ;
Gaddy, D ;
Suva, LJ .
CANCER RESEARCH, 2005, 65 (23) :11001-11009
[4]
Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease [J].
Bendre, MS ;
Montague, DC ;
Peery, T ;
Akel, NS ;
Gaddy, D ;
Suva, LJ .
BONE, 2003, 33 (01) :28-37
[5]
Calcium and bone disease [J].
Blair, Harry C. ;
Robinson, Lisa J. ;
Huang, Christopher L. -H. ;
Sun, Li ;
Friedman, Peter A. ;
Schlesinger, Paul H. ;
Zaidi, Mane .
BIOFACTORS, 2011, 37 (03) :159-167
[6]
Boraschi-Diaz I., 2014, CYTOTECHNOL IN PRESS
[7]
Osteoclast differentiation and activation [J].
Boyle, WJ ;
Simonet, WS ;
Lacey, DL .
NATURE, 2003, 423 (6937) :337-342
[8]
Targeted and nontargeted remodeling [J].
Burr, DB .
BONE, 2002, 30 (01) :2-4
[9]
Toll-like receptor 2 ligand mediates the upregulation of angiogenic factor, vascular endothelial growth factor and interleukin-8 CXCL8 in human rheumatoid synovial fibroblasts [J].
Cho, Mi-La ;
Ju, Ji-Hyeon ;
Kim, Hae-Rim ;
Oh, Hye-Joa ;
Kang, Chang-Min ;
Jhun, Joo-Yeon ;
Lee, Seon-Yeong ;
Park, Mi-Kyung ;
Min, Jun-Ki ;
Park, Sung-Hwan ;
Lee, Sang-Heon ;
Kim, Ho-Youn .
IMMUNOLOGY LETTERS, 2007, 108 (02) :121-128
[10]
Fitzgerald Oliver, 2012, J Rheumatol, V39, P427, DOI 10.3899/jrheum.111241